{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:10:01Z","timestamp":1777522201020,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1038\/ncpneuro0016","type":"journal-article","created":{"date-parts":[[2005,11,2]],"date-time":"2005-11-02T17:34:19Z","timestamp":1130952859000},"page":"34-44","source":"Crossref","is-referenced-by-count":32,"title":["Drug Insight: using monoclonal antibodies to treat multiple sclerosis"],"prefix":"10.1038","volume":"1","author":[{"given":"Reinhard","family":"Hohlfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Wekerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpneuro0016_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","volume":"359","author":"A Compston","year":"2002","unstructured":"Compston A and Coles A (2002) Multiple sclerosis. Lancet 359: 1221\u20131231","journal-title":"Lancet"},{"key":"BFncpneuro0016_CR2","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1056\/NEJM200009283431307","volume":"343","author":"JH Noseworthy","year":"2000","unstructured":"Noseworthy JH et al. (2000) Multiple sclerosis. N Engl J Med 343: 938\u2013952","journal-title":"N Engl J Med"},{"key":"BFncpneuro0016_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1212\/WNL.43.4.641","volume":"43","author":"BGW Arnason","year":"1993","unstructured":"Arnason BGW (1993) Interferon beta in multiple sclerosis. Neurology 43: 641\u2013643","journal-title":"Neurology"},{"key":"BFncpneuro0016_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1212\/WNL.58.2.169","volume":"58","author":"DS Goodin","year":"2002","unstructured":"Goodin DS et al. (2002) Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58: 169\u2013178","journal-title":"Neurology"},{"key":"BFncpneuro0016_CR5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0303-8467(02)00045-8","volume":"104","author":"DH Miller","year":"2002","unstructured":"Miller DH (2002) MRI monitoring of MS in clinical trials. Clin Neurol Neurosurg 104: 236\u2013243","journal-title":"Clin Neurol Neurosurg"},{"key":"BFncpneuro0016_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0896-6273(03)00326-X","volume":"38","author":"SS Zamvil","year":"2003","unstructured":"Zamvil SS and Steinman L (2003) Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron 38: 685\u2013688","journal-title":"Neuron"},{"key":"BFncpneuro0016_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","volume":"23","author":"M Sospedra","year":"2005","unstructured":"Sospedra M and Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23: 683\u2013747","journal-title":"Annu Rev Immunol"},{"key":"BFncpneuro0016_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.0105-2896.2005.00240.x","volume":"204","author":"DA Hafler","year":"2005","unstructured":"Hafler DA et al. (2005) Multiple sclerosis. Immunol Rev 204: 208\u2013231","journal-title":"Immunol Rev"},{"key":"BFncpneuro0016_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrn784","volume":"3","author":"B Hemmer","year":"2002","unstructured":"Hemmer B et al. (2002) New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3: 291\u2013301","journal-title":"Nat Rev Neurosci"},{"key":"BFncpneuro0016_CR10","doi-asserted-by":"publisher","first-page":"S14599","DOI":"10.1073\/pnas.0404874101","volume":"101 (Suppl 2)","author":"R Hohlfeld","year":"2004","unstructured":"Hohlfeld R and Wekerle H (2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 101 (Suppl 2): S14599\u2013S14606","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0016_CR11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/brain\/120.5.865","volume":"120","author":"R Hohlfeld","year":"1997","unstructured":"Hohlfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120: 865\u2013916","journal-title":"Brain"},{"key":"BFncpneuro0016_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev.iy.07.040189.002203","volume":"7","author":"H Waldmann","year":"1989","unstructured":"Waldmann H (1989) Manipulation of T-cell responses with monoclonal antibodies. Annu Rev Immunol 7: 407\u2013444","journal-title":"Annu Rev Immunol"},{"key":"BFncpneuro0016_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1749-6632.1988.tb27171.x","volume":"540","author":"DA Hafler","year":"1988","unstructured":"Hafler DA and Weiner HL (1988) Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human antimouse responses. Ann N Y Acad Sci 540: 557\u2013559","journal-title":"Ann N Y Acad Sci"},{"key":"BFncpneuro0016_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.36.6.777","volume":"36","author":"DA Hafler","year":"1986","unstructured":"Hafler DA et al. (1986) Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. Neurology 36: 777\u2013784","journal-title":"Neurology"},{"key":"BFncpneuro0016_CR15","volume-title":"Curing MS: How Science is Solving the Mysteries of Multiple Sclerosis","author":"HL Weiner","year":"2004","unstructured":"Weiner HL (2004) Curing MS: How Science is Solving the Mysteries of Multiple Sclerosis. New York: Crown Publishers"},{"key":"BFncpneuro0016_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ana.410220121","volume":"22","author":"DA Hafler","year":"1987","unstructured":"Hafler DA and Weiner HL (1987) In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis. Ann Neurol 22: 89\u201393","journal-title":"Ann Neurol"},{"key":"BFncpneuro0016_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nri1130","volume":"3","author":"RM Ransohoff","year":"2003","unstructured":"Ransohoff RM et al. (2003) Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3: 569\u2013581","journal-title":"Nat Rev Immunol"},{"key":"BFncpneuro0016_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1212\/WNL.41.7.1047","volume":"41","author":"BG Weinshenker","year":"1991","unstructured":"Weinshenker BG et al. (1991) An open trial of OKT3 in patients with multiple sclerosis. Neurology 41: 1047\u20131052","journal-title":"Neurology"},{"key":"BFncpneuro0016_CR19","first-page":"S21","volume":"26 (Suppl 14)","author":"LJ Swinnen","year":"1999","unstructured":"Swinnen LJ (1999) Overview of posttransplant B-cell lymphoproliferative disorders. Semin Oncol 26 (Suppl 14): S21\u2013S25","journal-title":"Semin Oncol"},{"key":"BFncpneuro0016_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nri1000","volume":"3","author":"L Chatenoud","year":"2003","unstructured":"Chatenoud L (2003) CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 3: 123\u2013132","journal-title":"Nat Rev Immunol"},{"key":"BFncpneuro0016_CR21","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1056\/NEJMoa043980","volume":"352","author":"Keymeulen","year":"2005","unstructured":"Keymeulen et al. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. New Engl J Med 352: 2598\u20132608","journal-title":"New Engl J Med"},{"key":"BFncpneuro0016_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/135245859600100404","volume":"1","author":"L Rumbach","year":"1996","unstructured":"Rumbach L et al. (1996) Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients. Mult Scler 1: 207\u2013212","journal-title":"Mult Scler"},{"key":"BFncpneuro0016_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1212\/WNL.49.2.351","volume":"49","author":"BW van Oosten","year":"1997","unstructured":"van Oosten BW et al. (1997) Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49: 351\u2013357","journal-title":"Neurology"},{"key":"BFncpneuro0016_CR24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.48.4.810","volume":"48","author":"N Llewellyn-Smith","year":"1997","unstructured":"Llewellyn-Smith N et al. (1997) Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412. Neurology 48: 810\u2013816","journal-title":"Neurology"},{"key":"BFncpneuro0016_CR25","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1172\/JCI119396","volume":"99","author":"MH Rep","year":"1997","unstructured":"Rep MH et al. (1997) Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. J Clin Invest 99: 2225\u20132231","journal-title":"J Clin Invest"},{"key":"BFncpneuro0016_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ni1178","volume":"6","author":"S Sakaguchi","year":"2005","unstructured":"Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345\u2013352","journal-title":"Nat Immunol"},{"key":"BFncpneuro0016_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1084\/jem.192.3.393","volume":"192","author":"H Babbe","year":"2000","unstructured":"Babbe H et al. (2000) Clonal expansion of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192: 393\u2013404","journal-title":"J Exp Med"},{"key":"BFncpneuro0016_CR28","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1073\/pnas.0308689100","volume":"101","author":"C Skulina","year":"2004","unstructured":"Skulina C et al. (2004) Multiple sclerosis: Brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci USA 101: 2428\u20132433","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0016_CR29","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","volume":"47","author":"BW van Oosten","year":"1996","unstructured":"van Oosten BW et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531\u20131534","journal-title":"Neurology"},{"key":"BFncpneuro0016_CR30","doi-asserted-by":"crossref","unstructured":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group (1999) Neurology 53: 457\u2013465","DOI":"10.1212\/WNL.53.3.457"},{"key":"BFncpneuro0016_CR31","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","volume":"57","author":"NL Sicotte","year":"2001","unstructured":"Sicotte NL and Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57: 1885\u20131888","journal-title":"Neurology"},{"key":"BFncpneuro0016_CR32","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N et al. (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44: 2862\u20132869","journal-title":"Arthritis Rheum"},{"key":"BFncpneuro0016_CR33","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098\u20131104","journal-title":"N Engl J Med"},{"key":"BFncpneuro0016_CR34","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","volume":"64","author":"GP Rice","year":"2005","unstructured":"Rice GP et al. (2005) Anti-\u03b14 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64: 1336\u20131342","journal-title":"Neurology"},{"key":"BFncpneuro0016_CR35","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nrd1752","volume":"4","author":"L Steinman","year":"2005","unstructured":"Steinman L (2005) Case history: Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 4: 510\u2013518","journal-title":"Nat Rev Drug Discov"},{"key":"BFncpneuro0016_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMoa020696","volume":"348","author":"DH Miller","year":"2003","unstructured":"Miller DH et al. (2003) A controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15\u201323","journal-title":"N Engl J Med"},{"key":"BFncpneuro0016_CR37","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK and Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369\u2013374","journal-title":"N Engl J Med"},{"key":"BFncpneuro0016_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A et al. (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375\u2013381","journal-title":"N Engl J Med"},{"key":"BFncpneuro0016_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Van Assche","year":"2005","unstructured":"Van Assche G et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362\u2013368","journal-title":"N Engl J Med"},{"key":"BFncpneuro0016_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1056\/NEJMe058122","volume":"353","author":"JR Berger","year":"2005","unstructured":"Berger JR and Koralnik IJ (2005) Progressive multifocal leukoencephalopathy and natalizumab\u2014unforeseen consequences. N Engl J Med 353: 414\u2013416","journal-title":"N Engl J Med"},{"key":"BFncpneuro0016_CR41","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1474-4422(04)00879-8","volume":"3","author":"BA t'Hart","year":"2004","unstructured":"t'Hart BA et al. (2004) Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol 3: 588\u2013597","journal-title":"Lancet Neurol"},{"key":"BFncpneuro0016_CR42","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1172\/JCI119110","volume":"98","author":"MG Wing","year":"1996","unstructured":"Wing MG et al. (1996) Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a\/CD18 (LFA-1) on NK cells. J Clin Invest 98: 2819\u20132826","journal-title":"J Clin Invest"},{"key":"BFncpneuro0016_CR43","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","volume":"354","author":"AJ Coles","year":"1999","unstructured":"Coles AJ et al. (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354: 1691\u20131695","journal-title":"Lancet"},{"key":"BFncpneuro0016_CR44","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#","volume":"46","author":"AJ Coles","year":"1999","unstructured":"Coles AJ et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46: 296\u2013304","journal-title":"Ann Neurol"},{"key":"BFncpneuro0016_CR45","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(94)91339-0","volume":"344","author":"T Moreau","year":"1994","unstructured":"Moreau T et al. (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344: 298\u2013301","journal-title":"Lancet"},{"key":"BFncpneuro0016_CR46","doi-asserted-by":"publisher","first-page":"8705","DOI":"10.1073\/pnas.0402653101","volume":"101","author":"B Bielekova","year":"2004","unstructured":"Bielekova B et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101: 8705\u20138708","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0016_CR47","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/ana.20287","volume":"56","author":"JW Rose","year":"2004","unstructured":"Rose JW et al. (2004) Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 56: 864\u2013867","journal-title":"Ann Neurol"},{"key":"BFncpneuro0016_CR48","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1084\/jem.20040812","volume":"200","author":"C Baecher-Allan","year":"2004","unstructured":"Baecher-Allan C and Hafler DA (2004) Suppressor T cells in human diseases. J Exp Med 200: 273\u2013276","journal-title":"J Exp Med"},{"key":"BFncpneuro0016_CR49","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1084\/jem.20031579","volume":"199","author":"V Viglietta","year":"2004","unstructured":"Viglietta V et al. (2004) Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199: 971\u2013979","journal-title":"J Exp Med"},{"key":"BFncpneuro0016_CR50","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1212\/WNL.63.12_suppl_6.S47","volume":"63 (Suppl 6)","author":"SA Rizvi","year":"2004","unstructured":"Rizvi SA and Bashir K (2004) Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 63 (Suppl 6): S47\u2013S54","journal-title":"Neurology"},{"key":"BFncpneuro0016_CR51","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BA Cree","year":"2005","unstructured":"Cree BA et al. (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64: 1270\u20131272","journal-title":"Neurology"},{"key":"BFncpneuro0016_CR52","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/archneur.62.2.258","volume":"62","author":"NL Monson","year":"2005","unstructured":"Monson NL et al. (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62: 258\u2013264","journal-title":"Arch Neurol"},{"key":"BFncpneuro0016_CR53","unstructured":"National Multiple Sclerosis Society USA [http:\/\/www.nationalmssociety.org\/research.asp]"},{"key":"BFncpneuro0016_CR54","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/ana.10146","volume":"51","author":"J Killestein","year":"2002","unstructured":"Killestein J et al. (2002) Antibody-mediated suppression of Vbeta5.2\/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. Ann Neurol 51: 467\u2013474","journal-title":"Ann Neurol"},{"key":"BFncpneuro0016_CR55","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G and Milstein C (1975) Continuous cultures of fused cells secreting antibody components of isologous erythrocytes. Nature 256: 495\u2013497","journal-title":"Nature"},{"key":"BFncpneuro0016_CR56","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri1265","volume":"4","author":"SS Alkan","year":"2004","unstructured":"Alkan SS (2004) Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nat Rev Immunol 4: 153\u2013156","journal-title":"Nat Rev Immunol"},{"key":"BFncpneuro0016_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nrd984","volume":"2","author":"OH Brekke","year":"2003","unstructured":"Brekke OH and Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2: 52\u201362","journal-title":"Nat Rev Drug Discov"},{"key":"BFncpneuro0016_CR58","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(00)01034-5","volume":"355","author":"FC Breedveld","year":"2000","unstructured":"Breedveld FC (2000) Therapeutic monoclonal antibodies. Lancet 355: 735\u2013740","journal-title":"Lancet"},{"key":"BFncpneuro0016_CR59","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1056\/NEJM200107263450409","volume":"345","author":"LE Schnipper","year":"2001","unstructured":"Schnipper LE and Strom TB (2001) A magic bullet for cancer\u2014how near and how far? N Engl J Med 345: 283\u2013284","journal-title":"N Engl J Med"},{"key":"BFncpneuro0016_CR60","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0167-5699(00)01680-7","volume":"21","author":"M Clark","year":"2000","unstructured":"Clark M (2000) Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today 21: 397\u2013402","journal-title":"Immunol Today"},{"key":"BFncpneuro0016_CR61","unstructured":"Lublin F et al. (1999) A phase II trial of anti-CD11\/CD18 monoclonal antibody in acute exacerbations of multiple sclerosis [abstract #290]. Neurology 52 (Suppl 2)"}],"container-title":["Nature Clinical Practice Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0016","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncpneuro0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:24:07Z","timestamp":1684441447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneuro0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["BFncpneuro0016"],"URL":"https:\/\/doi.org\/10.1038\/ncpneuro0016","relation":{},"ISSN":["1745-834X","1745-8358"],"issn-type":[{"value":"1745-834X","type":"print"},{"value":"1745-8358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}